CTRI/2023/04/051321尚未招募Unknown
Evaluation of Hemoglobinopathies in Cases of Microcytic Hypochromic Anemia by High Performance Liquid Chromatography
Bhagat Phool Singh Govt. Medical College, Khanpur Kalan, Sonepat0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Blood samples of patients with microcytic hypochromic anemia received for detection of hemoglobinopathies.
排除标准
- •Patients with history of blood transfusion within past three months.
研究者
相似试验
尚未招募
3 期
low haemoglobin with recurrent allergic rhinitisCTRI/2023/07/055342Self
尚未招募
不适用
Comparative study to compare non invasive device with an invasive device to measure hemoglobin values for guiding in blood transfusion in major oncosurgeriesCTRI/2021/03/031716Dr Ram Manohar Lohia Institute of Medical Sciences
进行中（未招募）
1 期
Study to evaluate long term effect of an experimental approach of gene therapy to treat ß-thalassemia major, know also as transfusion dependent ß-thalassemia, and the sickle cell disease.Subjects treated with gene therapy drug products in a bluebird bio-sponsored study will be invited to participate in this long-term follow-up study to monitor the safety and efficacy of the drug products. To date, subjects in this study have been treated with bluebird bio gene therapy drug products developed to treat the following indications:beta-thalassaemia majorSickle cell diseaseMedDRA version: 20.1Level: LLTClassification code 10055579Term: Sickle-cell beta thalassemiaSystem Organ Class: 100000004850EUCTR2013-002245-11-ITBLUEBIRD BIO, INC.94
进行中（未招募）
1 期
ASubjects treated with gene therapy drug products in a bluebird bio-sponsored study will be invited to participate in this long-term follow-up study to monitor the safety and efficacy of the drug products. To date, subjects in this study have been treated with bluebird bio gene therapy drug products developed to treat the following indications:beta-thalassaemia majorSickle cell diseaseMedDRA version: 20.1Level: LLTClassification code 10055579Term: Sickle-cell beta thalassemiaSystem Organ Class: 100000004850EUCTR2013-002245-11-GBbluebird bio, Inc.94
进行中（未招募）
1 期
ASubjects treated with gene therapy drug products in a bluebird bio-sponsored study will be invited to participate in this long-term follow-up study to monitor the safety and efficacy of the drug products. To date, subjects in this study have been treated with bluebird bio gene therapy drug products developed to treat the following indications:beta-thalassaemia majorSickle cell diseaseMedDRA version: 20.1Level: LLTClassification code 10055579Term: Sickle-cell beta thalassemiaSystem Organ Class: 100000004850EUCTR2013-002245-11-DEbluebird bio, Inc.94